INTRODUCTION

Cholangiocarcinoma (CCA) is a rare tumor comprising approximately 3% of gastrointestinal tumors with an overall incidence of less than 2/100 000. It is the second most common primary hepatic malignancy following hepatocellular carcinoma (HCC). The incidence of CCA has been increasing globally during the last decades, where its incidence increases with age.

According to the anatomic location, CCA is classified into intrahepatic (IH-CCA) and extrahepatic (EH-CCA) where the later accounts for 80%-90% of all cases. The commonest risk factors for CCA are primary sclerosing cholangitis (PSC), chronic liver disease (including chronic viral hepatitis B and C), and intrahepatic stones (hepatolithiasis).

CCA patients remain clinically silent until the advanced stages of the disease. The common clinical feature of EH-CCA is biliary obstruction resulting in painless jaundice, while IH-CCA presents in most cases...
miRNA-150 has been down-regulated in esophageal squamous cell carcinoma and colorectal cancer. In IH-CCA, it has been reported that plasma levels of miRNA150 were higher than healthy subjects in a small sample of patients. However, Wu et al documented that serum miRNA-150 level was down-regulated in CCA patients. Thus, under different cellular microenvironments, miRNA-150 may carry out different functions. Therefore, the role of miRNA-150 in CCA has yet to be more elucidated.

1.1 | Aim of work

The aim of the current work was to study the serum expression level of MiRNA-150-5P in CCA patients and, also, to correlate its level with tumor staging and different clinical and laboratory findings of the studied patients.

2 | SUBJECTS AND METHODS

The present study included 35 patients with CCA (randomly selected both intra- and extrahepatic CCA), who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age- and sex-matched healthy subjects were included as a control group (Group II) to obtain normal range of biochemical assays.

Diagnosis of CCA depended on CT and/or MRCP, ERCP with brush cytology (whenever needed). Also, the studied CCA patients had positive CA19-9. Patients with other malignancies, systemic diseases (as hepatic, renal, cardiac, or respiratory diseases), sepsis, and collagenic diseases (as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis) were excluded. Also, all our studied CCA patients (Group I) and normal control subjects (Group II) had negative HCV Abs and HBs Ag.

All included patients were submitted to the following:

- Detailed history taking with emphasis on age, gender, yellow skin and sclera, itching, abdominal pain, anorexia and nausea, vomiting, weight loss, and change in the color of urine and stool.
- Clinical examination including both general and local abdominal examination (hepatomegaly, abdominal mass, and palpable gallbladder).
- Laboratory investigations including complete blood count (CBC), liver biochemical profile, and serum CA19-9 level by radioimmunoassay (RIA).
- Serum expression of miRNA-150-5p level measured by real-time polymerase chain reaction (RT-PCR).

2.1 | Method

Total serum RNA was isolated using miRNeasy Mini Kit (QIAGEN) Cat No./ID: 217004, according to the manufacturer’s protocol.
Briefly, 5 μL of 5 nMol/L Syn-cel-miR-39 (miScriptmiRNA Mimic) was added to each sample as a spike-in control, and then, total RNA was purified from 400 μL of sample. The miRNeasy Mini Kit contains phenol/guanidine-based lysis of samples and silica membrane-based purification of total RNA. Samples were homogenized in Qiazol Lysis Reagent. After addition of chloroform, the homogenate was separated into aqueous and organic phases by centrifugation. RNA partitions to the upper, aqueous phase. The upper, aqueous phase was extracted, and ethanol was added to provide appropriate binding conditions for all RNA. The sample was then applied to the RNeasy Mini spin column, where the total RNA binds to the membrane and phenol and other contaminants are efficiently washed away. High-quality RNA is then eluted in RNase-free water. The concentration of total RNA samples from plasma was quantified by a Nanodrop 2000 (Nanodrop, USA). The range of the result was from 11.9 to 73.7 ng/μL.

The TaqMan MicroRNA Reverse Transcription (RT) Kit supplied by Applied Biosystems was used for the reverse transcription reaction. The recommended reaction volume was 20 μL. The plate was prepared, and ABI prism 7900 sequence detection system (Ambion) was used for amplification and detection by RT-PCR. Differences in serum miR-150-5p expression were normalized to cel-miR-39, determined with the ΔCt method, and reported as 2⁻ΔΔCt.

### Statistical analysis

Quantitative data of the present work were analyzed, using F-test (ANOVA) and post hoc test (Scheffe) for pairwise comparison. All statistical calculations were performed using IBM SPSS software package version 20.0, where P < .05 was considered statistically significant.

The study was approved by the Research Ethics Committee of the Faculty of Medicine, University of Alexandria, and was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. An informed consent was obtained from all subjects included in the study.

### RESULTS

#### 3.1 Demographic data

In the present study, age showed a median of 54 years and 57 years in Group I and Group II, respectively, with no statistical significant difference between both groups. As regards sex, males predominated females in both studied groups.

#### 3.2 Serum CA19-9 and MiRNA-150-5p expression levels

Table 1 showed comparison between both studied groups according to serum CA19-9 and miRNA-150-5p expression levels. Serum CA19-9 levels showed an evident high median among CCA (Group I) patients in comparison with normal control (Group II) subjects (413 U/mL and 20 U/mL, respectively). On the contrast, serum MiRNA-150-5p expression levels showed an evident low median among CCA (Group I) patients in comparison with normal control (Group II) subjects (0.04 and 1.03, respectively). An evident statistical significant difference was reported between both studied groups, where \( P < .001 \).

#### 3.3 Correlation between serum CA19-9 and MiRNA-150-5p expression levels in CCA (Group I) patients

Table 2 showed negative correlation between serum CA19-9 and miRNA-150-5p expression levels, where \( P = .001 \).

#### 3.4 Correlation between serum MiRNA-150-5p expression level and different studied parameters in CCA (Group I) patients

Table 3 showed negative correlation between serum MiRNA-150-5p expression level and different studied parameters as well as TNM staging of CCA patients.

### Table 1

Comparison between the two studied groups according to serum CA19-9 and MiRNA-150-5p expression levels

|                | Group I (n = 35) | Group II (n = 35) | U     | P    |
|----------------|-----------------|-------------------|-------|------|
| CA 19-9 (U/mL) |                 |                   |       |      |
| Min. – Max.    | 3.98 - 3200.0   | 3.39 - 268.0      | 41.0* | <.001*|
| Mean ± S       | 908.13 ± 1004   | 35.8 ± 82.40      |       |      |
| Median         | 413.0           | 20.0              |       |      |
| MiRNA-150-5p   |                 |                   |       |      |
| Min. – Max.    | 0.003 - 1.89    | 0.017 - 4.16      | 110.0*| .001*|
| Mean ± S       | 0.17 ± 0.38     | 1.23 ± 1.48       |       |      |
| Median         | 0.04            | 1.03              |       |      |

Note: U, P: U and P values for Mann-Whitney test for comparing between the two groups.

*Statistically significant at \( P \leq .05 \).
3.5 | Receiver operating characteristic (ROC) analysis to study the ability of serum CA19-9, MiRNA-150-5p expression and combination of both for the diagnosis of CCA

Figures 1-3 showed the accuracy and efficacy for the diagnosis of CCA by serum CA19-9, serum MiRNA-150-5p expression, and combining both of them. Figure 4A,B showed the fluorescence signal versus cycle number for both target MiRNA-150-5p expression and spike-in control cel-mirna-39.

4 | DISCUSSION

CCA is a tumor with high mortality rate and is consistently asymptomatic in the early stages. Its diagnosis and staging require a multimodality approach involving laboratory, radiologic, endoscopic, and pathologic analyses. Therefore, the identification of new diagnostic and prognostic biomarkers for CCA with proper sensitivity and specificity is urgently needed.

Studies have revealed that circulating miRNAs may be potential diagnostic markers in diverse diseases, especially in the field of malignant neoplasms. Hu et al reported that miRNA-31 was significantly up-regulated in CCA tissues, while Li et al found that miRNA-214 was significantly lower in CCA tissues compared with normal tissues. Also, Oishi et al found that the expression of miRNA-200 was low in CCA and was correlated negatively with overall survival and disease-free survival.

MiRNA-150 was found to have two contrary roles in malignant tumors. It was demonstrated that it promotes tumorigenesis in various cancers as it exerts its oncogenic function through down-regulation of the expression of the pro-apoptotic purinergic P2X7 receptor in epithelial cell cancer, and by targeting the pro-apoptotic gene epidermal growth factor (EGR2) as in gastric cancer. On the contrary, other studies revealed that miRNA-150 may act as a tumor-suppressor miRNA, where it was found to be down-regulated in esophageal squamous cell carcinoma, and it inhibited the growth and malignant behavior of pancreatic cancer cells by targeting mucin 4 (MUC4). Thus, whether miRNA-150 function as oncogenes or tumor suppressors is dependent on the cell and tumor type.

In the current study, serum CA19-9 levels showed an evident high median among CCA patients which was in agreement previous studies. On the other hand, serum miRNA-150-5p expression

| TABLE 2 | Correlation between serum CA19-9 and MiRNA-150-5p expression levels in CCA (Group I) patients |
| CA19-9 U/mL | MiRNA-150-5p expression | \( r_s \) | \( P \) |
|-----------|-----------------|-------|---|
|            | MiRNA-150-5p expression | -.533* | <.001* |

Note: \( r_s \): Spearman coefficient.

*Statistically significant at \( P \leq .05 \).

| TABLE 3 | Correlation between serum MiRNA-150-5p expression level and different studied parameters in CCA (Group I) patients |
| MiRNA-150-5p | \( r \) | \( P \) |
|-------------|-------|---|
| Age (y)         | .149  | .392 |
| Hb (g/dL)      | .128  | .463 |
| Leukocytes \( \times 10^3 \) | .194  | .264 |
| Platelets \( \times 10^3 \)    | .198  | .255 |
| ALT (IU/L)     | -.370* | .029* |
| AST (IU/L)     | -.188  | .279 |
| Total bilirubin (mg/dL)    | -.426* | .011* |
| Direct bilirubin (mg/dL)    | -.366* | .031* |
| Alkaline phosphatase (U/L)  | -.337* | .048* |
| GGT (U/L)       | -.199  | .251 |

Clinical presentation

| Jaundice     | -.538* | .001* |
| Itching      | -.538* | .001* |
| Abdominal pain | .117  | .504 |
| Anorexia and nausea | .111  | .526 |
| Vomiting     | -.658* | <.001* |
| Weight loss  | .093   | .595 |
| Change in color of urine | -.538* | .001* |
| Change in color of stool | -.538* | .001* |
| Hepatomegaly | .098   | .577 |
| TNM staging (I, II, III, IV) | -.674* | <.001* |

Note: \( r \): Pearson coefficient.

*Statistically significant at \( P \leq .05 \).
levels showed an evident low median among CCA patients which was in agreement with the finding previously observed by Wu et al., who reported that serum miRNA-150 expression level was down-regulated in CCA patients. They stated that miRNA-150 was bound to an oncogene Ets including gene-1 (ELK1), and Western blot data confirmed that miRNA-150 suppressed ELK1 expression in CCA cell lines used in this study. These findings suggest that reduced miRNA-150 expression in CCA patients is related to tumor development and progression. Also, Chang et al. reported that miRNA-150 was down-regulated by c-Myc, the later acts as one of the most common oncogenic events in human cancers, including CCA.

On the other hand, Wang et al. reported contrary expression profiles of miRNA-150 between the tumor tissues and blood samples. Authors found that miRNA-150 expression was down-regulated in the IH-CCA tissues, while its plasma level was significantly higher in comparison with the controls. The difference between the extracellular and cellular miRNA-150 profiles may be explained by the hypothesis of cellular selection mechanism of miRNA release. Based on this hypothesis, miRNA-150 is an exocrine agent released by peritumoral non-cancerous cells and may act as an important negative feedback regulating agent. Yet, the exact mechanism for this difference between tissue and plasma miRNA profiles is not clear and needs to be further studied.

In the present study, negative correlation between serum CA19-9 and MiRNA-150-5p expression levels in CCA patients (Group I) was reported. This result was in agreement with Wu et al. who stated that serum miRNA-150 expression level was inversely associated with serum CA19-9 level in CCA patients. This tumor suppressor action was demonstrated by Bioinformatic Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses which showed that miRNA-150 could regulate several gene pathways, including cancer pathway low expression of miRNA-150 enhances proliferation, migration, and invasion capability of CCA cells. This action may explain the negative correlation with CA19-9.

For better understanding of the implications of serum miRNA-150-5p, its expression levels were correlated with clinical and laboratory findings in the current study. There was a negative correlation between serum miRNA-150-5p expression level and ALT, serum bilirubin, alkaline phosphatase, jaundice, itching, vomiting, change in the color of urine and stool, and TNM staging. Our results were in accordance with Wu et al. who stated that serum miRNA-150 level was inversely associated with pathological grades of CCA which in turn affect clinical and laboratory data.

On the other hand, Wang et al. reported that there was no correlation between miRNA-150 level and different studied laboratory parameters. They found that the miRNA-150 level was not affected by serum albumin, total bilirubin, alanine, and aspartate aminotransferase levels as well as other clinical indices.

In the present study, CA19-9 ability for the diagnosis of CCA at a cutoff value of 167 U/mL had a sensitivity of 85.7% and a specificity of 93.33%, and our results were in agreement with previous studies. Moreover, serum miRNA-150-5p expression ability for the diagnosis of CCA had 91.43% sensitivity and 80% specificity. By combining both serum CA19-9 and miRNA-150-5p expression, high accuracy and efficacy for the diagnosis of CCA were found. The sensitivity was raised to 93.33% and specificity to 96.88%, and this was in agreement with Wang et al. who reported that combining miRNA-150 with CA19-9 made the sensitivity and specificity for the diagnosis of CCA 80% and 100%, respectively.
ACKNOWLEDGMENTS
The authors thank all the contributors of this work.

CONFLICT OF INTEREST
There is no conflict of interest in this work.

AUTHORS CONTRIBUTIONS
Dr Perihan Salem formed the idea of the research, assessed the included patients, and wrote the paper. Dr Rasha Ghazala performed the laboratory work and revised the paper. Dr Ahmed El Gendi involved in collection of the cases and revised the paper. Dr Doaa Emara involved in imaging and revised the paper. Dr Nesma Ahmed involved in collection of the cases, performed the statistical analysis, and revised the paper.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE
The study was approved by the Research Ethics Committee of the Faculty of Medicine, University of Alexandria, and was conducted...
in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Also, an informed consent was obtained from all subjects included in the study.

CONSENT FOR PUBLICATION
All the contributing authors agreed for the publication in this journal.

DATA AVAILABILITY STATEMENT
All the data related to this work are available at the corresponding author.

ORCID
Perihan El Sayed Salem https://orcid.org/0000-0002-8383-4136

REFERENCES

1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221-232.
2. Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):245-252.
3. Sripa B, Paipojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24(3):349-356.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. J Gastroenterol Hepatol. 2011;8(9):512-522.
5. Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg. 2008;25(2):126-132.
6. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.
7. Lee CC, Wu CY, Chen GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol. 2002;17(9):1015-1020.
8. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(6):1-9.
9. Foley WD, Quiroz FA. The role of sonography in imaging of the biliary tract. Ultrasound Q. 2007;23(2):123-135.
10. Zandrino F, Benzi L, Ferretti ML, Ferrando R, Reggiani G, Musante F. Multislice CT cholangiography without biliary contrast agent: technique and initial clinical results in the assessment of patients with biliary obstruction. Eur Radiol. 2002;12(5):1155-1161.
11. Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):155-164.
12. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000;6(6):30-34.
13. Coelho-Prabhu N, Baron TH. Endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholangiocarcinoma. Clin Liver Dis. 2010;14(2):333-348.
14. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma—the influence of sampling time and hepatolithiasis. Hepatogastroenterology. 2002;49(45):616-620.
15. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45(1):54-61.
16. Nehils O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004;24(2):139-154.
17. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19–9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9(5):434-439.
18. Jansson MD, Lund AH. MicroRNA and cancer. Molecular Oncology. 2012;6(6):590-610.
19. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9(6):703-711.
20. Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol. 2011;55(4):111-118.
21. Liu F, Xiong Y, Zhao Y, et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray. Diag Pathol. 2013;8:158.
22. Chen L, Yan H-X, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009;50:358-369.
23. Fang F, Ren X, Zhang X. Role of microRNA-150 in solid tumors. OncoLett. 2015;10:11-16.
24. Huang S, Chen Y, Wu W, et al. MiR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PloS One. 2013;8(12):e80707.
25. Gao M, Hou D, Liang H, et al. MiR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signaling inhibitor 1. Eur J Cancer. 2014;50(5):1013-1024.
26. Wu Q, Jin H, Yang Z, et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 2010;392(3):340-345.
27. Srivastava SK, Bhawardj A, Singh S, et al. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 2011;32(12):1832-1839.
28. Okobori T, Suzuki S, Tanaka N, et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2013;104(1):48-54.
29. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447-1453.
30. Wang S, Yin J, Li T, et al. Upreregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma. Oncol Rep. 2015;33(2):819-825.
31. Wu X, Xia M, Chen D, et al. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma. Tumor Biology. 2016;37(11):15019-15029.
32. Bragazzi MC, Cardinale V, Carpino G, et al. Cholangiocarcinoma: epidemiology and risk factors. Translational Gastrointestinal Cancer. 2011;1(1):21-32.
33. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12(1):131-150.
34. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med. 2013;6(5):1265-1270.
35. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012;279(13):2393-2398.
36. Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012;56:1792-1803.
37. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski GI. MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3’ untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem. 2008;283(42):28274-28286.
38. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
39. Suarez-Munoz MA, Fernandez-Aguilar JL, Sanchez-Perez B, et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013;5(7):132-138.
40. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol. 2004;10(3):427-432.
41. Chang T-C, Yu D, Lee Y-S, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50.
42. Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammaryepithelial cells. PLoS One. 2010;5:13515.
43. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31(1):7-11.
44. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50(9):1734-1740.

How to cite this article: Salem PES, Ghazala RA, El Gendi AM, Emara DM, Ahmed NM. The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal. 2020;34:e23397. https://doi.org/10.1002/jcla.23397